Retinal gene therapy: current progress and future prospects

References

• Daiger SP, Bowne SJ, Sullivan LS. Perspective on genes and mutations causing retinitis pigmentosa. Arch Ophthalmol 2007;125(2):151-8
   PubMedGoogle Scholar
• UTHealth. Available from: https://sph.uth.edu/
   Google Scholar
• Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 2008;358(21):2231-9
   PubMed Web of Science ®Google Scholar
• Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008;19(10):979-90
   PubMed Web of Science ®Google Scholar
• Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 2008;358(21):2240-8
   PubMed Web of Science ®Google Scholar
• Buch PK, Bainbridge JW, Ali RR. AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther 2008;15(11):849-57
   PubMed Web of Science ®Google Scholar
• Han Z, Conley SM, Makkia RS, et al. DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. J Clin Invest 2012;122(9):3221-6
   PubMed Web of Science ®Google Scholar
• Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012;130(1):9-24
   PubMed Web of Science ®Google Scholar
• Jacobson SG, Aleman TS, Cideciyan AV, et al. Defining the Residual Vision in Leber Congenital Amaurosis Caused by RPE65 Mutations. Invest Ophthalmol Vis Sci 2009;50(5):2368-75
   PubMedGoogle Scholar
• Thompson DA, Gyurus P, Fleischer LL, et al. Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration. Invest Ophthalmol Vis Sci 2000;41(13):4293-9
   PubMed Web of Science ®Google Scholar
• Perrault I, Rozet JM, Ghazi I, et al. Different functional outcome of RetGC1 and RPE65 gene mutations in Leber congenital amaurosis. Am J Hum Genet 1999;64(4):1225-8
   PubMedGoogle Scholar
• Hanein S, Perrault I, Gerber S, et al. Leber congenital amaurosis: comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, and genotype-phenotype correlations as a strategy for molecular diagnosis. Hum Mutat 2004;23(4):306-17
   PubMed Web of Science ®Google Scholar
• Paunescu K, Wabbels B, Preising MN, Lorenz B. Longitudinal and cross-sectional study of patients with early-onset severe retinal dystrophy associated with RPE65 mutations. Graefes Arch Clin Exp Ophthalmol 2005;243(5):417-26
   PubMedGoogle Scholar
• Jacobson SG, Aleman TS, Cideciyan AV, et al. Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci USA 2005;102(17):6177-82
   PubMed Web of Science ®Google Scholar
• Hamel CP, Jenkins NA, Gilbert DJ, et al. The gene for the retinal pigment epithelium-specific protein RPE65 is localized to human 1p31 and mouse 3. Genomics 1994;20(3):509-12
   PubMedGoogle Scholar
• Redmond TM, Yu S, Lee E, et al. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet 1998;20(4):344-51
   PubMed Web of Science ®Google Scholar
• Katz ML, Redmond TM. Effect of Rpe65 knockout on accumulation of lipofuscin fluorophores in the retinal pigment epithelium. Invest Ophthalmol Vis Sci 2001;42(12):3023-30
   PubMedGoogle Scholar
• Katz ML, Wendt KD, Sanders DN. RPE65 gene mutation prevents development of autofluorescence in retinal pigment epithelial phagosomes. Mech Ageing Dev 2005;126(4):513-21
   PubMedGoogle Scholar
• Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res 2010;29(5):398-427
   PubMed Web of Science ®Google Scholar
• Kaylor JJ, Yuan Q, Cook J, et al. Identification of DES1 as a vitamin A isomerase in Muller glial cells of the retina. Nat Chem Biol 2013;9(1):30-6
   PubMed Web of Science ®Google Scholar
• Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science 1965;149(3685):754-6
   PubMed Web of Science ®Google Scholar
• Muzyczka N, Samulski RJ, Hermonat P, et al. The genetics of adeno-associated virus. Adv Exp Med Biol 1984;179:151-61
   PubMed Web of Science ®Google Scholar
• Sprecher-Goldberger S, Thiry L, Lefebvre N, et al. Complement-fixation antibodies to adenovirus-associated viruses, cytomegaloviruses and herpes simplex viruses in patients with tumors and in control individuals. Am J Epidemiol 1971;94(4):351-8
   PubMedGoogle Scholar
• Willett K, Bennett J. Immunology of AAV-mediated gene transfer in the Eye. Front Immunol 2013;4:261
   PubMed Web of Science ®Google Scholar
• Samulski RJ, Berns KI, Tan M, Muzyczka N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 1982;79(6):2077-81
   PubMedGoogle Scholar
• Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 1984;81(20):6466-70
   PubMedGoogle Scholar
• Ni TH, Zhou X, McCarty DM, et al. In vitro replication of adeno-associated virus DNA. J Virol 1994;68(2):1128-38
   PubMedGoogle Scholar
• Zhou X, Muzyczka N. In vitro packaging of adeno-associated virus DNA. J Virol 1998;72(4):3241-7
   PubMedGoogle Scholar
• Bennicelli J, Wright JF, Komaromy A, et al. Reversal of blindness in animal models of Leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 2008;16(3):458-65
   PubMed Web of Science ®Google Scholar
• Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005;12(6):1072-82
   PubMed Web of Science ®Google Scholar
• Le Meur G, Stieger K, Smith AJ, et al. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 2007;14(4):292-303
   PubMed Web of Science ®Google Scholar
• Narfstrom K, Vaegan Katz M, et al. Assessment of structure and function over a 3-year period after gene transfer in RPE65-/- dogs. Doc Ophthalmol 2005;111(1):39-48
   PubMedGoogle Scholar
• Aguirre GK, Komaromy AM, Cideciyan AV, et al. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation. PLoS Med 2007;4(6):e230
   Google Scholar
• Jacobson SG, Acland GM, Aguirre GD, et al. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther 2006;13(6):1074-84
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Hauswirth WW, Aleman TS, et al. Vision 1 year after gene therapy for Leber’s congenital amaurosis. N Engl J Med 2009;361(7):725-7
   PubMedGoogle Scholar
• Cideciyan AV, Aguirre GK, Jacobson SG, et al. Pseudo-fovea formation after gene therapy for RPE65-LCA. Invest Ophthalmol Vis Sci 2014;56(1):526-37
   Google Scholar
• Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011;12(5):341-55
   PubMed Web of Science ®Google Scholar
• Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005;5(3):285-97
   PubMed Web of Science ®Google Scholar
• Lebherz C, Maguire A, Tang W, et al. Novel AAV serotypes for improved ocular gene transfer. J Gene Med 2008;10(4):375-82
   PubMedGoogle Scholar
• Beltran WA. The use of canine models of inherited retinal degeneration to test novel therapeutic approaches. Vet Ophthalmol 2009;12(3):192-204
   PubMedGoogle Scholar
• Yang GS, Schmidt M, Yan Z, et al. Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol 2002;76(15):7651-60
   PubMed Web of Science ®Google Scholar
• Auricchio A, Kobinger G, Anand V, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 2001;10(26):3075-81
   PubMed Web of Science ®Google Scholar
• Allocca M, Mussolino C, Garcia-Hoyos M, et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol 2007;81(20):11372-80
   PubMedGoogle Scholar
• Zhong L, Zhao W, Wu J, et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 2007;15(7):1323-30
   PubMedGoogle Scholar
• Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008;105(22):7827-32
   PubMed Web of Science ®Google Scholar
• Petrs-Silva H, Dinculescu A, Li Q, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009;17(3):463-71
   PubMed Web of Science ®Google Scholar
• Petrs-Silva H, Dinculescu A, Li Q, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011;19(2):293-301
   PubMed Web of Science ®Google Scholar
• Moskalenko M, Chen L, van Roey M, et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000;74(4):1761-6
   PubMed Web of Science ®Google Scholar
• Mitchell AM, Nicolson SC, Warischalk JK, Samulski RJ. AAV’s anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther 2010;10(5):319-40
   PubMed Web of Science ®Google Scholar
• Yang L, Xiao X. Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution. Virol J 2013;10:50
   PubMedGoogle Scholar
• Hida K, Hanes J, Ostermeier M. Directed evolution for drug and nucleic acid delivery. Adv Drug Deliv Rev 2007;59(15):1562-78
   PubMedGoogle Scholar
• Guziewicz KE, Zangerl B, Komaromy AM, et al. Recombinant AAV-mediated BEST1 transfer to the retinal pigment epithelium: analysis of serotype-dependent retinal effects. PLoS One 2013;8(10):e75666
   Google Scholar
• Conlon TJ, Deng WT, Erger K, et al. Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. Hum Gene Ther Clin Dev 2013;24(1):23-8
   PubMed Web of Science ®Google Scholar
• Olsson JE, Gordon JW, Pawlyk BS, et al. Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron 1992;9(5):815-30
   PubMedGoogle Scholar
• Tan E, Wang Q, Quiambao AB, et al. The relationship between opsin overexpression and photoreceptor degeneration. Invest Ophthalmol Vis Sci 2001;42(3):589-600
   PubMed Web of Science ®Google Scholar
• Mao H, James TJr, Schwein A, et al. AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Hum Gene Ther 2011;22(5):567-75
   PubMedGoogle Scholar
• Hashimoto T, Gibbs D, Lillo C, et al. Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B. Gene Ther 2007;14(7):584-94
   PubMed Web of Science ®Google Scholar
• Seo S, Mullins RF, Dumitrescu AV, et al. Subretinal gene therapy of mice with Bardet-Biedl syndrome type 1. Invest Ophthalmol Vis Sci 2013;54(9):6118-32
   PubMed Web of Science ®Google Scholar
• Beltran WA, Boye SL, Boye SE, et al. rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promoters. Gene Ther 2010;17(9):1162-74
   PubMedGoogle Scholar
• Boye SE, Alexander JJ, Boye SL, et al. The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina. Hum Gene Ther 2012;23(10):1101-15
   PubMed Web of Science ®Google Scholar
• Li Q, Timmers AM, Guy J, et al. Cone-specific expression using a human red opsin promoter in recombinant AAV. Vision Res 2008;48(3):332-8
   PubMedGoogle Scholar
• Glushakova LG, Timmers AM, Pang J, et al. Human blue-opsin promoter preferentially targets reporter gene expression to rat s-cone photoreceptors. Invest Ophthalmol Vis Sci 2006;47(8):3505-13
   PubMedGoogle Scholar
• Dyka FM, Boye SL, Ryals RC, et al. Cone specific promoter for use in gene therapy of retinal degenerative diseases. Adv Exp Med Biol 2014;801:695-701
   PubMedGoogle Scholar
• MacLaren RE, Groppe M, Barnard AR, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014;383(9923):1129-37
   PubMed Web of Science ®Google Scholar
• Dalkara D, Byrne LC, Klimczak RR, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013;5(189):189ra176
   Web of Science ®Google Scholar
• Kay CN, Ryals RC, Aslanidi GV, et al. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One 2013;8(4):e62097
   Google Scholar
• Mowat FM, Gornik KR, Dinculescu A, et al. Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach. Gene Ther 2014;21(1):96-105
   PubMed Web of Science ®Google Scholar
• Yin L, Greenberg K, Hunter JJ, et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011;52(5):2775-83
   PubMed Web of Science ®Google Scholar
• Dalkara D, Kolstad KD, Caporale N, et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 2009;17(12):2096-102
   PubMed Web of Science ®Google Scholar
• Allocca M, Doria M, Petrillo M, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 2008;118(5):1955-64
   PubMed Web of Science ®Google Scholar
• Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther 2010;18(1):80-6
   PubMed Web of Science ®Google Scholar
• Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol 2005;79(15):9933-44
   PubMed Web of Science ®Google Scholar
• Dong B, Nakai H, Xiao W. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther 2010;18(1):87-92
   PubMed Web of Science ®Google Scholar
• Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther 2001;4(4):383-91
   PubMed Web of Science ®Google Scholar
• Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA 2000;97(12):6716-21
   PubMed Web of Science ®Google Scholar
• Ghosh A, Yue Y, Lai Y, Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther 2008;16(1):124-30
   PubMed Web of Science ®Google Scholar
• Trapani I, Colella P, Sommella A, et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med 2014;6(2):194-211
   PubMed Web of Science ®Google Scholar
• Colella P, Trapani I, Cesi G, et al. Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors. Gene Ther 2014;21(4):450-6
   PubMed Web of Science ®Google Scholar
• Trapani I, Puppo A, Auricchio A. Vector platforms for gene therapy of inherited retinopathies. Prog Retin Eye Res 2014;43C:108-28
   Web of Science ®Google Scholar
• Balaggan KS, Binley K, Esapa M, et al. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J Gene Med 2006;8(3):275-85
   PubMed Web of Science ®Google Scholar
• Mazarakis ND, Azzouz M, Rohll JB, et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 2001;10(19):2109-21
   PubMed Web of Science ®Google Scholar
• O’Rourke JP, Hiraragi H, Urban K, et al. Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors. Mol Ther 2003;7(5 Pt 1):632-9
   PubMedGoogle Scholar
• O’Rourke JP, Olsen JC, Bunnell BA. Optimization of equine infectious anemia derived vectors for hematopoietic cell lineage gene transfer. Gene Ther 2005;12(1):22-9
   PubMedGoogle Scholar
• Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014;383(9923):1138-46
   PubMed Web of Science ®Google Scholar
• Azzouz M, Martin-Rendon E, Barber RD, et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson’s disease. J Neurosci 2002;22(23):10302-12
   PubMedGoogle Scholar
• Jarraya B, Boulet S, Ralph GS, et al. Dopamine gene therapy for Parkinson’s disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 2009;1(2):2ra4
   PubMed Web of Science ®Google Scholar
• Kong J, Kim SR, Binley K, et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther 2008;15(19):1311-20
   PubMed Web of Science ®Google Scholar
• Zallocchi M, Binley K, Lad Y, et al. EIAV-based retinal gene therapy in the shaker1 mouse model for usher syndrome type 1B: development of UshStat. PLoS One 2014;9(4):e94272
   Google Scholar
• Binley K, Widdowson P, Loader J, et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Invest Ophthalmol Vis Sci 2013;54(6):4061-71
   PubMed Web of Science ®Google Scholar
• Bainbridge JW, Stephens C, Parsley K, et al. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther 2001;8(21):1665-8
   PubMedGoogle Scholar
• Puppo A, Cesi G, Marrocco E, et al. Retinal transduction profiles by high-capacity viral vectors. Gene Ther 2014;21(10):855-65
   PubMedGoogle Scholar
• Lipinski DM, Barnard AR, Charbel Issa P, et al. Vesicular stomatitis virus glycoprotein- and Venezuelan equine encephalitis virus-derived glycoprotein-pseudotyped lentivirus vectors differentially transduce corneal endothelium, trabecular meshwork, and human photoreceptors. Hum Gene Ther 2014;25(1):50-62
   PubMed Web of Science ®Google Scholar
• Yanez-Munoz RJ, Balaggan KS, MacNeil A, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006;12(3):348-53
   PubMed Web of Science ®Google Scholar
• Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996;93(24):13565-70
   PubMed Web of Science ®Google Scholar
• Bennett J. Immune response following intraocular delivery of recombinant viral vectors. Gene Ther 2003;10(11):977-82
   PubMed Web of Science ®Google Scholar
• Cashman SM, McCullough L, Kumar-Singh R. Improved retinal transduction in vivo and photoreceptor-specific transgene expression using adenovirus vectors with modified penton base. Mol Ther 2007;15(9):1640-6
   PubMedGoogle Scholar
• Sweigard JH, Cashman SM, Kumar-Singh R. Adenovirus vectors targeting distinct cell types in the retina. Invest Ophthalmol Vis Sci 2010;51(4):2219-28
   PubMed Web of Science ®Google Scholar
• Fink TL, Klepcyk PJ, Oette SM, et al. Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene Ther 2006;13(13):1048-51
   PubMed Web of Science ®Google Scholar
• Ziady AG, Gedeon CR, Muhammad O, et al. Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol Ther 2003;8(6):948-56
   PubMed Web of Science ®Google Scholar
• Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004;15(12):1255-69
   PubMed Web of Science ®Google Scholar
• Han Z, Conley SM, Makkia R, et al. Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery. PLoS One 2012;7(12):e52189
   PubMed Web of Science ®Google Scholar
• Yew NS, Zhao H, Wu IH, et al. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol Ther 2000;1(3):255-62
   PubMed Web of Science ®Google Scholar
• Tsybovsky Y, Molday RS, Palczewski K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Adv Exp Med Biol 2010;703:105-25
   PubMed Web of Science ®Google Scholar
• Nagel-Wolfrum K, Baasov T, Wolfrum U. Therapy strategies for Usher syndrome Type 1C in the retina. Adv Exp Med Biol 2014;801:741-7
   PubMedGoogle Scholar
• Kachi S, Binley K, Yokoi K, et al. Equine infectious anemia viral vector-mediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits choroidal neovascularization. Hum Gene Ther 2009;20(1):31-9
   PubMedGoogle Scholar
• Binley K, Widdowson PS, Kelleher M, et al. Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat((R)), for age-related macular degeneration. Hum Gene Ther 2012;23(9):980-91
   PubMed Web of Science ®Google Scholar
• Shyong MP, Lee FL, Kuo PC, et al. Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. Mol Vis 2007;13:133-41
   PubMed Web of Science ®Google Scholar
• Raisler BJ, Berns KI, Grant MB, et al. Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci USA 2002;99(13):8909-14
   PubMedGoogle Scholar
• Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002;6(4):490-4
   PubMed Web of Science ®Google Scholar
• May CA, Ohlmann AV, Hammes H, Spandau UH. Proteins with an endostatin-like domain in a mouse model of oxygen-induced retinopathy. Exp Eye Res 2006;82(2):341-8
   PubMedGoogle Scholar
• Parker M, Bellec J, McFarland T, et al. Suppression of neovascularization of donor corneas by transduction with equine infectious anemia virus-based lentiviral vectors expressing endostatin and angiostatin. Hum Gene Ther 2014;25(5):408-18
   PubMedGoogle Scholar
• Pechan P, Rubin H, Lukason M, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 2009;16(1):10-16
   PubMedGoogle Scholar
• Maclachlan TK, Lukason M, Collins M, et al. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther 2011;19(2):326-34
   PubMed Web of Science ®Google Scholar
• Lukason M, DuFresne E, Rubin H, et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther 2011;19(2):260-5
   PubMedGoogle Scholar
• Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res 2012;31(3):195-212
   PubMed Web of Science ®Google Scholar
• Vijayasarathy C, Ziccardi L, Sieving PA. Biology of retinoschisin. Adv Exp Med Biol 2012;723:513-18
   PubMed Web of Science ®Google Scholar
• Park TK, Wu Z, Kjellstrom S, et al. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther 2009;16(7):916-26
   PubMedGoogle Scholar
• Marangoni D, Wu Z, Wiley HE, et al. Preclinical Safety Evaluation of a Recombinant AAV8 Vector for X-Linked Retinoschisis After Intravitreal Administration in Rabbits. Hum Gene Ther Clin Dev 2014;25(4):202-11
   PubMedGoogle Scholar
• Kjellstrom S, Bush RA, Zeng Y, et al. Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration. Invest Ophthalmol Vis Sci 2007;48(8):3837-45
   PubMedGoogle Scholar
• Larijani B, Hume AN, Tarafder AK, Seabra MC. Multiple factors contribute to inefficient prenylation of Rab27a in Rab prenylation diseases. J Biol Chem 2003;278(47):46798-804
   PubMedGoogle Scholar
• Charbel Issa P, Bolz HJ, Ebermann I, et al. Characterisation of severe rod-cone dystrophy in a consanguineous family with a splice site mutation in the MERTK gene. Br J Ophthalmol 2009;93(7):920-5
   PubMed Web of Science ®Google Scholar
• Mackay DS, Henderson RH, Sergouniotis PI, et al. Novel mutations in MERTK associated with childhood onset rod-cone dystrophy. Mol Vis 2010;16:369-77
   PubMed Web of Science ®Google Scholar
• Smith AJ, Schlichtenbrede FC, Tschernutter M, et al. AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. Mol Ther 2003;8(2):188-95
   PubMed Web of Science ®Google Scholar
• Deng WT, Dinculescu A, Li Q, et al. Tyrosine-mutant AAV8 delivery of human MERTK provides long-term retinal preservation in RCS rats. Invest Ophthalmol Vis Sci 2012;53(4):1895-904
   PubMedGoogle Scholar
• Pasadhika S, Fishman GA, Stone EM, et al. Differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis. Invest Ophthalmol Vis Sci 2010;51(5):2608-14
   PubMedGoogle Scholar
• Jacobson SG, Cideciyan AV, Peshenko IV, et al. Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. Hum Mol Genet 2013;22(1):168-83
   PubMedGoogle Scholar
• Boye SL, Conlon T, Erger K, et al. Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest Ophthalmol Vis Sci 2011;52(10):7098-108
   PubMedGoogle Scholar
• Boye SL, Peshenko IV, Huang WC, et al. AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis. Hum Gene Ther 2013;24(2):189-202
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Aleman TS, Jacobson SG, et al. Centrosomal-ciliary gene CEP290/NPHP6 mutations result in blindness with unexpected sparing of photoreceptors and visual brain: implications for therapy of Leber congenital amaurosis. Hum Mutat 2007;28(11):1074-83
   PubMedGoogle Scholar
• Cideciyan AV, Rachel RA, Aleman TS, et al. Cone photoreceptors are the main targets for gene therapy of NPHP5 (IQCB1) or NPHP6 (CEP290) blindness: generation of an all-cone Nphp6 hypomorph mouse that mimics the human retinal ciliopathy. Hum Mol Genet 2011.20(7):1411-23
   Google Scholar
• Boye SE, Huang WC, Roman AJ, et al. Natural history of cone disease in the murine model of Leber congenital amaurosis due to CEP290 mutation: determining the timing and expectation of therapy. PLoS One 2014;9(3):e92928
   Google Scholar
• Narfstrom K, Holland Deckman K, Menotti-Raymond M. The domestic cat as a large animal model for characterization of disease and therapeutic intervention in hereditary retinal blindness. J Ophthalmol 2011;2011:906943
   PubMedGoogle Scholar
• Mancuso K, Hendrickson AE, Connor TBJr, et al. Recombinant adeno-associated virus targets passenger gene expression to cones in primate retina. J Opt Soc Am A Opt Image Sci Vis 2007;24(5):1411-16
   PubMedGoogle Scholar
• Yang P, Michaels KV, Courtney RJ, et al. Retinal morphology of patients with achromatopsia during early childhood: implications for gene therapy. JAMA Ophthalmol 2014;132(7):823-31
   PubMedGoogle Scholar
• Aboshiha J, Dubis AM, Cowing J, et al. A prospective longitudinal study of retinal structure and function in achromatopsia. Invest Ophthalmol Vis Sci 2014;55(9):5733-43
   PubMedGoogle Scholar
• Dubis AM, Cooper RF, Aboshiha J, et al. Genotype-dependent variability in residual cone structure in achromatopsia: toward developing metrics for assessing cone health. Invest Ophthalmol Vis Sci 2014;55(11):7303-11
   PubMedGoogle Scholar
• Komaromy AM, Alexander JJ, Rowlan JS, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet 2010;19(13):2581-93
   PubMed Web of Science ®Google Scholar
• Michalakis S, Muhlfriedel R, Tanimoto N, et al. Restoration of cone vision in the CNGA3-/- mouse model of congenital complete lack of cone photoreceptor function. Mol Ther 2010;18(12):2057-63
   PubMedGoogle Scholar
• Pang JJ, Deng WT, Dai X, et al. AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS One 2012;7(4):e35250
   PubMed Web of Science ®Google Scholar
• Ezra-Elia R, Banin E, Honig H, et al. Flicker cone function in normal and day blind sheep: a large animal model for human achromatopsia caused by CNGA3 mutation. Doc Ophthalmol 2014;129(3):141-50
   PubMedGoogle Scholar
• Raghupathy RK, McCulloch DL, Akhtar S, et al. Pathogenesis of X-linked RP3: insights from animal models. Adv Exp Med Biol 2014;801:477-85
   PubMedGoogle Scholar
• Beltran WA, Cideciyan AV, Lewin AS, et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci USA 2012;109(6):2132-7
   PubMed Web of Science ®Google Scholar
• Millington-Ward S, Chadderton N, O’Reilly M, et al. Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther 2011;19(4):642-9
   PubMed Web of Science ®Google Scholar
• Leveillard T, Mohand-Said S, Lorentz O, et al. Identification and characterization of rod-derived cone viability factor. Nat Genet 2004;36(7):755-9
   PubMedGoogle Scholar
• Yang Y, Mohand-Said S, Danan A, et al. Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol Ther 2009;17(5):787-95
   PubMedGoogle Scholar
• Byrne LC, Dalkara D, Luna G, et al. Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration. J Clin Invest 2015;125(1):105-16
   PubMed Web of Science ®Google Scholar
• G N, Tan A, Farhatnia Y, et al. Channelrhodopsins: visual regeneration and neural activation by a light switch. N Biotechnol 2013;30(5):461-74
   PubMedGoogle Scholar
• Mutter M, Swietek N, Munch TA. Salvaging ruins: reverting blind retinas into functional visual sensors. Methods Mol Biol 2014;1148:149-60
   PubMedGoogle Scholar
• Bi A, Cui J, Ma YP, et al. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron 2006;50(1):23-33
   PubMed Web of Science ®Google Scholar
• Thyagarajan S, van Wyk M, Lehmann K, et al. Visual function in mice with photoreceptor degeneration and transgenic expression of channelrhodopsin 2 in ganglion cells. J Neurosci 2010;30(26):8745-58
   PubMedGoogle Scholar
• Rolling F. Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives. Gene Ther 2004;11(Suppl 1):S26-32
   Google Scholar
• Clinical trials.gov home page. U.S. National Institutes of Health. Available from: https://ClinicalTrials.gov [Accessed 07 March 2015]
   Google Scholar
• Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis. Available from: https://clinicaltrials.gov/ct2/show/NCT00643747
   Google Scholar
• Phase I trial of gene vector to patients with retinal disease due to RPE65 Mutations (LCA). Available from: https://clinicaltrials.gov/ct2/show/NCT00481546
   Google Scholar
• Safety study in subjects with Leber congenital amaurosis. Available from: https://clinicaltrials.gov/ct2/show/NCT00516477
   Google Scholar
• Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009;374(9701):1597-605
   PubMed Web of Science ®Google Scholar
• Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber’s congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18(3):643-50
   PubMed Web of Science ®Google Scholar
• Ashtari M, Cyckowski LL, Monroe JF, et al. The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest 2011;121(6):2160-8
   PubMedGoogle Scholar
• Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012;4(120):120ra115
   Web of Science ®Google Scholar
• Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 2013;120(6):1283-91
   PubMed Web of Science ®Google Scholar
• Phase 1/2 safety and efficacy study of AAV-RPE65 vector to treat leber congenital amaurosis. Available from: https://clinicaltrials.gov/ct2/show/NCT00749957
   Google Scholar
• Stout T, Weleber R, McBride M, et al. Treatment of patients with Leber congenital amaurosis type 2 with an AAV vector expressing RPE65. Invest Ophthalmol Vis Sci 2013;54: E-Abstract 5964
   Google Scholar
• Clinical trial of gene therapy for Leber congenital amaurosis caused by RPE65 Mutations. Available from: https://clinicaltrials.gov/ct2/show/NCT00821340
   Google Scholar
• Banin E, Bandah-Rozenfeld D, Obolensky A, et al. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum Gene Ther 2010;21(12):1749-57
   PubMedGoogle Scholar
• Clinical gene therapy protocol for the treatment of retinal dystrophy Caused by Defects in RPE65. Available from: https://clinicaltrials.gov/ct2/show/NCT01496040
   Google Scholar
• Le Meur G, Lebranchu P, Pereon Y, et al. Efficacy and safety of gene therapy with AAV4 in childhood blindness due to rpe65 mutations. Acta Ophthalmologica 2012;90(Suppl S249):0
   Google Scholar
• Safety and efficacy study in subjects with Leber congenital amaurosis. Available from: https://clinicaltrials.gov/ct2/show/NCT00999609
   Google Scholar
• Phase 1 follow-on study of AAV2-hRPE65v2 vector in subjects with Leber congenital amaurosis (LCA) 2. Available from: https://clinicaltrials.gov/ct2/show/NCT01208389
   Google Scholar
• Phase I/IIa study of stargen in patients with Stargardt’s macular degeneration. Available from: https://clinicaltrials.gov/ct2/show/NCT01367444
   Google Scholar
• Study of ushstat in patients with retinitis pigmentosa associated with usher syndrome type 1B. Available from: https://clinicaltrials.gov/ct2/show/NCT01505062
   Google Scholar
• Gene therapy for blindness caused by choroideremia. Available from: https://clinicaltrials.gov/ct2/show/NCT01461213
   Google Scholar
• Safety and dose escalation study of AAV2-hCHM in subjects with CHM (Choroideremia) gene mutations. Available from: https://clinicaltrials.gov/ct2/show/NCT02341807
   Google Scholar
• Tolmachova T, Tolmachov OE, Barnard AR, et al. Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo. J Mol Med (Berl) 2013;91(7):825-37
   PubMed Web of Science ®Google Scholar
• Black A, Vasireddy V, Chung DC, et al. Adeno-associated virus 8-mediated gene therapy for choroideremia: preclinical studies in in vitro and in vivo models. J Gene Med 2014;16(5-6):122-30
   PubMed Web of Science ®Google Scholar
• An open label clinical trial of retinal gene therapy for choroideremia. Available from: https://clinicaltrials.gov/ct2/show/NCT02077361
   Google Scholar
• Trial of ocular subretinal injection of a recombinant adeno-associated virus (rAAV2-VMD2-hMERTK) gene vector to patients with retinal disease due to MERTK Mutations. Available from: https://clinicaltrials.gov/ct2/show/NCT01482195
   Google Scholar
• Phase I dose escalation safety study of retinostat in advanced age-related macular degeneration (AMD) (GEM). Available from: https://clinicaltrials.gov/ct2/show/NCT01301443
   Google Scholar
• Safety and tolerability study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD). Available from: https://clinicaltrials.gov/ct2/show/NCT01024998
   Google Scholar
• Safety and efficacy study of rAAV.sFlt-1 in patients with exudative age-related macular degeneration (AMD). Available from: https://clinicaltrials.gov/ct2/show/NCT01494805
   Google Scholar
• Study of RS1 ocular gene transfer for X-linked Retinoschisis. Available from: https://clinicaltrials.gov/ct2/show/NCT02317887
   Google Scholar
• AGTC. Available from: www.agtc.com/products/achromatopsia [Accessed 08 March 2015]
   Google Scholar
• Carvalho LS, Xu J, Pearson RA, et al. Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet 2011;20(16):3161-75
   PubMedGoogle Scholar
• Genable. Available from: www.genable.net/genable-technology [Accessed 08 March 2015]
   Google Scholar
• CHM gene therapy at University of Alberta. Available from: www.chmgenetherapy.ca/ [Last accessed 08 March 2015]
   Google Scholar
• Spark therapeutics. Available from: www.sparktx.com/pipeline/inherited-retinal-dystrophies [Accessed 08 March 2015]
   Google Scholar
• Genzyme. Available from: http://news.genzyme.com/press-release/genzyme-collaborates-gene-therapy-rare-disease-causes-childhood-blindness [Accessed 08 March 2015]
   Google Scholar
• Mihelec M, Pearson RA, Robbie SJ, et al. Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of Leber congenital amaurosis caused by guanylate cyclase-1 deficiency. Hum Gene Ther 2012;22(10):1179-90
   Google Scholar
• AGTC. Available from: www.agtc.com/products/x-linked-retinitis-pigmentosa [Accessed 08 March 2015]
   Google Scholar
• AGTC. Available from: www.agtc.com/products/x-Linked-retinoschisis [Accessed 08 March 2015]
   Google Scholar
• Zeng Y, Takada Y, Kjellstrom S, et al. RS-1 Gene Delivery to an Adult Rs1h Knockout Mouse Model Restores ERG b-Wave with Reversal of the Electronegative Waveform of X-Linked Retinoschisis. Invest Ophthalmol Vis Sci 2004;45(9):3279-85
   PubMedGoogle Scholar
• Takada Y, Vijayasarathy C, Zeng Y, et al. Synaptic pathology in retinoschisis knockout (Rs1-/y) mouse retina and modification by rAAV-Rs1 gene delivery. Invest Ophthalmol Vis Sci 2008;49(8):3677-86
   PubMedGoogle Scholar